Clinical Trials Logo

Clinical Trial Summary

This study investigates how often abnormal findings from routine magnetic resonance imaging occur in people with genetic mutations in BReast CAncer gene. (BRCA), ataxia telangiectasia mutated gene (ATM), or PALB2 screened for pancreatic cancer. This study may lead to a greater understanding of cancer and potentially, improvements in cancer screening and treatment.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To determine the event rate of abnormal magnetic resonance imaging (MRI) findings in screened study participants. SECONDARY OBJECTIVES: I. To determine the rates of high-grade pancreatic neoplasia precursors (intraductal papillary mucinous neoplasm (IPMN)-high-grade dysplasia (HGD)) and pancreatic intraepithelial neoplasia-3 [PanIN-3]) and pancreatic ductal adenocarcinoma (PDAC) among all study participants. II. To understand rates of procedures (biopsies and surgeries) among all study participants. EXPLORATORY OBJECTIVES: I. To create a biorepository of all participants through the collection of saliva, blood, and tissue, combined with imaging findings and robust clinical annotation of patient health behaviors in all study participants. II. To explore knowledge, attitudes, and anxiety related to pancreatic cancer screening at annual intervals in all study participants. OUTLINE: Participants are assigned to 1 of 2 groups. GROUP I: Participants may opt to undergo MRI/ magnetic resonance cholangiopancreatography (MRCP) annually for 10 years or complete questionnaires over 10 minutes and undergo blood, saliva and tissue sample collection. GROUP II: Participants undergo MRI/MRCP screening annually for 10 years. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05058846
Study type Observational
Source University of California, San Francisco
Contact Phu Lam
Phone (415) 353-8337
Email [email protected]
Status Not yet recruiting
Start date November 15, 2021
Completion date December 31, 2031

See also
  Status Clinical Trial Phase
Recruiting NCT04602026 - Re-Defining Frailty and Improving Outcomes Through Prehabilitation in Patients With Pancreatic, Liver, or Gastric Cancer, The RIOT Trial N/A
Not yet recruiting NCT04965311 - Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy Phase 2
Recruiting NCT03645148 - Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer Phase 1
Recruiting NCT02587689 - Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor Phase 1/Phase 2
Not yet recruiting NCT04905082 - HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics N/A
Recruiting NCT02676349 - Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) Phase 2
Not yet recruiting NCT04870034 - Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer Early Phase 1
Active, not recruiting NCT03267524 - Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers N/A
Recruiting NCT04147494 - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues Early Phase 1
Recruiting NCT03164486 - First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide Early Phase 1
Active, not recruiting NCT02009449 - A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors Phase 1
Terminated NCT03137706 - Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer
Completed NCT03962478 - Combined Stent Insertion and HIFU Ablation for Pancreatic Carcinoma With Biliary Obstruction N/A
Recruiting NCT03849469 - A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors Phase 1
Terminated NCT00907166 - A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients Phase 1/Phase 2
Recruiting NCT03752398 - A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) Phase 1
Completed NCT03949933 - Proton and Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer N/A
Withdrawn NCT01814631 - Endoscopic Ultrasound (EUS) Processor Comparison N/A
Not yet recruiting NCT03785743 - Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma N/A
Completed NCT02807844 - Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies Phase 1/Phase 2